SCHEMBL6432225

SCHEMBL6432225

COc1ccc(/C=N/Nc2nc3nonc3nc2Nc2ccc(Cl)c(Cl)c2)c(O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
MAPT P10636 7/20 0.40
RAB9A P51151 4/20 0.40
PKM P14618 2/20 0.40
EPHA2 P29317 2/20 0.40
KDR P35968 2/20 0.40
MEN1 O00255 8/20 0.40
KMT2A Q03164 8/20 0.40
NPC1 O15118 5/20 0.40
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
CCR2 P41597 1/20 0.38
CCR5 P51681 1/20 0.38
POLB P06746 3/20 0.38
RECQL P46063 1/20 0.38
HTT P42858 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432233 1.00 GAA (0.44) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6417041 0.93 KMT2A (0.43) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6417039 0.93 KMT2A (0.43) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6432537 0.92 APP (0.42) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6432545 0.92 APP (0.42) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6416491 0.89 MEN1 (0.49) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6436116 0.88 FADS1 (0.44) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6436122 0.88 FADS1 (0.44) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6438165 0.87 GAA (0.45) GAASMN1; SMN2TP53MAPTRAB9A
SCHEMBL6503461 0.87 GAA (0.45) GAASMN1; SMN2TP53MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 GAA 3186/4885SMN1; SMN2 4369/4885TP53 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.